RXRX Q1 2023 Earnings — Recursion Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RXRXRecursion Pharmaceuticals, Inc.

$2B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$12M+129.0% YoY

Gross Profit

-$314,000-2.6% margin

Operating Income

-$70M-575.8% margin

Net Income

-$65M-538.4% margin

EPS (Diluted)

$-0.32

QoQ Revenue Growth

-11.3%

Cash Flow

Operating Cash Flow

-$73M

Free Cash Flow

-$79M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$627M

Total Liabilities

$197M

Stockholders' Equity

$430M

Cash & Equivalents

$473M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12M	$5M	+129.0%
Gross Profit	-$314,000	-$3M	+87.4%
Operating Income	-$70M	-$56M	-24.8%
Net Income	-$65M	-$56M	-16.7%

Revenue Segments

License and Service

$12M100%